Skip to main content
GHRS
NASDAQ Life Sciences

GH Research Establishes $200M At-The-Market Equity Offering Program

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
8
Price
$21.57
Mkt Cap
$1.5B
52W Low
$9.456
52W High
$24.66
Market data snapshot near publication time

summarizeSummary

GH Research PLC launched a new At-The-Market (ATM) equity offering program to sell up to $200 million in shares, potentially diluting existing shareholders and signaling continued capital requirements.


check_boxKey Events

  • New At-The-Market Offering

    GH Research PLC entered into a Sales Agreement to offer and sell up to $200 million of ordinary shares through an At-The-Market (ATM) program, effective May 14, 2026.

  • Substantial Potential Dilution

    The $200 million offering, if fully utilized, represents a substantial potential dilution to existing shareholders.

  • Follows Recent Capital Raise

    This ATM program is established shortly after an underwritten offering on April 29, 2026, which raised over $111 million by selling 6,527,779 shares at $18.00 each.

  • Use of Proceeds

    Net proceeds are intended for strategic investment in research, clinical and technical development of product candidates, pre-commercialization activities, working capital, capital expenditures, and general corporate purposes.


auto_awesomeAnalysis

GH Research PLC has established a new At-The-Market (ATM) equity offering program, allowing it to sell up to $200 million of ordinary shares from time to time. This program represents a substantial potential dilution to existing shareholders if fully utilized. It follows closely on the heels of a significant underwritten offering completed on April 29, 2026, which raised over $111 million. The continuous capital raising efforts, while providing necessary funding for R&D and general corporate purposes, indicate ongoing financial needs and could create an overhang on the stock price due to potential future dilution.

At the time of this filing, GHRS was trading at $21.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $9.46 to $24.66. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed GHRS - Latest Insights

GHRS
May 14, 2026, 9:20 AM EDT
Filing Type: F-3
Importance Score:
8
GHRS
May 14, 2026, 9:02 AM EDT
Filing Type: 424B5
Importance Score:
8
GHRS
May 14, 2026, 7:21 AM EDT
Filing Type: 6-K
Importance Score:
7
GHRS
Apr 29, 2026, 8:26 AM EDT
Filing Type: 424B5
Importance Score:
8
GHRS
Apr 29, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
GHRS
Apr 20, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
GHRS
Mar 25, 2026, 11:10 AM EDT
Source: GlobeNewswire
Importance Score:
7
GHRS
Mar 05, 2026, 7:08 AM EST
Source: Dow Jones Newswires
Importance Score:
8
GHRS
Mar 05, 2026, 7:04 AM EST
Filing Type: 6-K
Importance Score:
7
GHRS
Jan 15, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
9